Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report.
Adipose derived-mesenchymal stem cells
Case report
Early osteoarthritis
First metatarsophalangeal joint arthritis
Hallux rigidus
Regenerative medicine
Stem cells
Journal
World journal of orthopedics
ISSN: 2218-5836
Titre abrégé: World J Orthop
Pays: United States
ID NLM: 101576349
Informations de publication
Date de publication:
18 Jan 2021
18 Jan 2021
Historique:
received:
27
07
2020
revised:
05
10
2020
accepted:
20
10
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
First metatarsophalangeal joint arthritis (FMTPA), also known as hallux rigidus, is the most frequent degenerative disease of the foot. Diagnosis is made through both clinical and radiological evaluation. Regenerative medicine showed promising results in the treatment of early osteoarthritis. The aim of the present study was to report the results of a case of FMTPA treated with the injection of autologous adipose-derived mesenchymal stem cells. A gentleman of 50 years of age presented with a painful hallux rigidus grade 2 resistant to any previous conservative treatment (including nonsteroidal anti-inflammatory drugs and hyaluronic acid injections). An injection of autologous adipose-derived mesenchymal stem cells into the first metatarsophalangeal joint was performed. No adverse events were reported, and both function and pain scales improved after 9 mo of follow-up. The FMTP joint injection of mesenchymal stem cells improved symptoms and function in our patient with FMTPA at 9 mo of follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
First metatarsophalangeal joint arthritis (FMTPA), also known as hallux rigidus, is the most frequent degenerative disease of the foot. Diagnosis is made through both clinical and radiological evaluation. Regenerative medicine showed promising results in the treatment of early osteoarthritis. The aim of the present study was to report the results of a case of FMTPA treated with the injection of autologous adipose-derived mesenchymal stem cells.
CASE SUMMARY
METHODS
A gentleman of 50 years of age presented with a painful hallux rigidus grade 2 resistant to any previous conservative treatment (including nonsteroidal anti-inflammatory drugs and hyaluronic acid injections). An injection of autologous adipose-derived mesenchymal stem cells into the first metatarsophalangeal joint was performed. No adverse events were reported, and both function and pain scales improved after 9 mo of follow-up.
CONCLUSION
CONCLUSIONS
The FMTP joint injection of mesenchymal stem cells improved symptoms and function in our patient with FMTPA at 9 mo of follow-up.
Identifiants
pubmed: 33520681
doi: 10.5312/wjo.v12.i1.51
pmc: PMC7814311
doi:
Types de publication
Case Reports
Langues
eng
Pagination
51-55Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that they had no conflict of interest.
Références
Phys Sportsmed. 2004 Jul;32(7):41-5
pubmed: 20086421
Injury. 2019 Jul;50 Suppl 2:S75-S79
pubmed: 30846284
EFORT Open Rev. 2017 Mar 13;2(1):13-20
pubmed: 28607766
Int Orthop. 2019 Jan;43(1):7-13
pubmed: 30280218
Ther Adv Musculoskelet Dis. 2017 Aug;9(8):183-196
pubmed: 28835778
Regen Med. 2018 Apr;13(3):295-307
pubmed: 29417902
Nat Clin Pract Rheumatol. 2008 Jul;4(7):371-80
pubmed: 18477997
Ann Rheum Dis. 2011 Oct;70(10):1838-41
pubmed: 21791454
Am J Sports Med. 2018 Dec;46(14):3550-3563
pubmed: 29099618
Expert Rev Clin Immunol. 2013 Feb;9(2):175-84
pubmed: 23390948
Aging (Albany NY). 2016 Aug;8(8):1703-17
pubmed: 27490266
Joints. 2017 Aug 11;5(3):152-155
pubmed: 29270545
Arthroscopy. 2019 Jan;35(1):277-288.e2
pubmed: 30455086
Int J Mol Sci. 2018 Jun 30;19(7):
pubmed: 29966351
J Bone Joint Surg Am. 2003 Nov;85(11):2072-88
pubmed: 14630834
Clin Cases Miner Bone Metab. 2017 Sep-Dec;14(3):317-323
pubmed: 29354160
Cell Commun Signal. 2011 May 14;9:12
pubmed: 21569606
Foot Ankle Int. 2007 Jan;28(1):38-42
pubmed: 17257536
Rev Esp Cir Ortop Traumatol. 2014 Nov-Dec;58(6):377-86
pubmed: 25088241